Piper Sandler analyst Allison Bratzel downgraded IO Biotech (IOBT) to Neutral from Overweight with a price target of 50c, down from $3.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech Explores Strategic Alternatives Amid Cost-Cutting Plans
- IO Biotech announces exploration of strategic alternatives
- IO Biotech downgraded to Underweight from Equal Weight at Morgan Stanley
- IO Biotech Receives Nasdaq Notice for Bid Price Noncompliance
- IO Biotech publishes MM1636 trial results in Nature Communications